AstraZeneca inks drug development deal with Compugen

Apr 02, 2018

AstraZeneca has entered into a licensing deal with Israeli-based Compugen to make cancer treatments.

The companies said that under the agreement AstraZeneca’s research unit will develop engineered antibody products from Compugen’s drug oncology pipeline. Compugen is paying $100 million upfront for the deal, but could receive up to $200 million in royalties on the new treatments.

Compugen said the deal will help secure future research into cancer treatments.

Read the full Reuters report.